ABSTRACT: Lipid nanoparticles (LNPs) are formulated using unmodified cholesterol. However, cholesterol is naturally esterified and oxidized in vivo, and these cholesterol variants are differentially trafficked in vivo via lipoproteins including LDL and VLDL. We hypothesized that incorporating the same cholesterol variants into LNPswhich can be structurally similar to LDL and VLDLwould alter nanoparticle targeting in vivo. To test this hypothesis, we quantified how >100 LNPs made with six cholesterol variants delivered DNA barcodes to 18 cell types in wild-type, LDLR −/− , and VLDLR −/− mice that were both age-matched and female. By analyzing ∼2000 in vivo drug delivery data points, we found that LNPs formulated with esterified cholesterol delivered nucleic acids more efficiently than LNPs formulated with regular or oxidized cholesterol when compared across all tested cell types in the mouse. We also identified an LNP containing cholesteryl oleate that efficiently delivered siRNA and sgRNA to liver endothelial cells in vivo. Delivery was asor moreefficient as the same LNP made with unmodified cholesterol. Moreover, delivery to liver endothelial cells was 3 times more efficient than delivery to hepatocytes, distinguishing this oleate LNP from hepatocyte-targeting LNPs. RNA delivery can be improved by rationally selecting cholesterol variants, allowing optimization of nanoparticle targeting.
In vivo drug delivery is a complex process that is difficult to predict. 1, 2 The relationship between in vitro and in vivo delivery can be nonexistent, 3 demonstrating the utility of testing hundreds of nanoparticles in vivo. 3 Recently, DNA barcodebased technologies have enabled scientists to study many nanoparticles in vivo simultaneously. 3−5 Here we sought to improve nucleic acid delivery mediated by lipid nanoparticles (LNPs) by systematically studying the relationship between LNP chemical structure and in vivo delivery.
We focused on cholesterol variants in the LNP for several reasons. Many laboratories have studied how the structure of hundreds of cationic or ionizable lipid-like biomaterials in LNPs affect delivery in vitro; 6−11 in vivo structure function studies using more than a few LNPs have not been published. LNPs are created ("formulated") by mixing these lipid-like biomaterials with other constituents, most often PEG-lipids 12 and unmodified cholesterol. However, cholesterol is naturally oxidized or esterified in vivo. Oxidized cholesterol is typically found within oxidized LDL (ox-LDL). LDL oxidation is partially driven by diet, the presence of reactive oxygen species, and other factors. 13 Esterification of cholesterol occurs at different sites (e.g., peripheral tissues, liver), enabling more compact storage and transportation of cholesterol.
14 Esterification of cholesterol from peripheral tissues is mediated by lecithin-cholesterol acyltransferase on the surface of nascent HDL and by acyl-COA-cholesterol acyltransferase intracellularly. 15, 16 These cholesterol "variants" are also actively trafficked to cells including hepatocytes, endothelial cells, and macrophages. 14 The amount of different cholesterol variants also changes with many common diseases (e.g., high cholesterol, atherosclerosis, hyperlipidemia, diabetes), 17 suggesting that LNP trafficking may change with the disease state of the patient. For instance, ox-LDL is pro-atherosclerotic and pro-inflammatory and contributes to the amount of reactive oxygen species (ROS) in the bloodstream. 18−21 Increases in ox-LDL are related to atherosclerosis and other heart disease. 22−25 Despite these facts, the relationship between cholesterol structure and in vivo LNP delivery remains unexplored.
We hypothesized that the structure of cholesterol included in LNPs affects targeting in vivo. This hypothesis has important implications. It suggests LNP targeting can be tuned using naturally or synthetically derived cholesterol variants; this is critical given the need for LNPs that deliver RNAs to cell types other than hepatocytes. 26 It also implies that LNPs may behave differently in patients with aberrant cholesterol levels. For instance, patients with aberrant metabolisms may have increased amounts of oxidative stress, leading to a higher presence of oxidized cholesterol, creating positive feedback. 27 In patients with dyslipidemia, this positive feedback loop can start as a change in lipoprotein core structure, particularly a decrease in cholesteryl esters and cholesterol and an increased chance of oxidation. 28 This is important given the growing clinical use of LNPs that deliver siRNAs 29 and the high percentage of patients that have aberrant cholesterol levels. We tested our hypothesis in wild-type mice as well as low density lipoprotein receptor (LDLR) and very low density lipoprotein receptor (VLDLR) knockout mice. Both mouse models are regularly used to study cholesterol dysfunction. 30, 31 LDLR
and VLDLR −/− mice are typically given high-fat diets to induce metabolic disease. Herein we examined nanoparticle delivery in strain-and age-matched wild-type (WT) controls for mice fed a normal diet, such that the only difference would be LDLR or VLDLR expression.
Other groups have studied the relationship between nanoparticles and gene expression. 32, 33 Our current work complements these studies but is distinct. These studies used a small number of nanoparticles to test the hypothesis that a specific gene influenced nanoparticle delivery. In contrast, we used >100 LNPs to test the hypothesis that cholesterol structure affects LNP delivery. We formulated 141 LNPs with six cholesterol variants based on natural lipoproteins. We administered all the LNPs in vivo at once to WT, LDLR −/− , or VLDLR −/− mice using high-throughput LNP DNA barcoding 3, 4 and isolated cells using fluorescence activated cell sorting (FACS). Using a nanoparticle bioinformatics pipeline, we found that LNPs formulated with esterified cholesterol increased LNP distribution relative to LNPs with regular or oxidized cholesterol in WT mice when averaging nanoparticle distribution across all cell types analyzed. Based on the in vivo screen, we identified an LNP enriched in hepatic endothelial cells. As predicted by the in vivo nanoparticle barcoding screen, the LNP efficiently delivered therapeutic nucleic acids to hepatic endothelial cells, which have been refractory to systemic nanoparticle targeting.
RESULTS AND DISCUSSION
We used high-throughput DNA barcoding 3, 4 to assess how cholesterol variants altered LNP biodistribution. LNPs can be made with a similar size and composition to LDL and VLDL ( Figure 1A) , two lipoproteins that interact with the LDLR and VLDLR ( Figure 1B) . We formulated 141 LNPs using esterified, oxidized, or unmodified cholesterol ( Figure 1C ,D, Supplementary Figure 1A ). All LNPs were formulated using the validated biomaterial 7C1. 6 Of the 141, 111 met our inclusion criteria: autocorrelation curves with one inflection point and hydrodynamic diameters between 20 and 200 nm, based on dynamic light scattering (DLS) ( Figure 1E ,F, Supplementary Figure 1B) . These 111 LNPs, along with a naked DNA barcode, which served as a negative control, were pooled together and intravenously administered to WT, LDLR −/− , and VLDLR −/− mice at a total DNA dose of 0.5 mg/kg (0.0045 mg/kg/barcode 
CD45
− ) using FACS 3,6,34−36 (Supplementary Figure 1C−E) . Seventy-two hours is suffi- ciently long for LNPs to be cleared from the bloodstream. 6 All three cell types play critical roles in cholesterol trafficking. Macrophages are known to take up oxidized cholesterol via scavenger receptor-mediated endocytosis of ox-LDL, one of the initial steps in the formation of foam cells, which are critical to the progression of atherosclerosis 37−39 Hepatocytes also play a critical role by synthesizing cholesterol in the liver and responding to internal increases or decreases in cholesterol by up-or down-regulating production of LDLR. 40, 41 Finally, endothelial cells actively interact with serum lipoproteins to maintain cholesterol homeostasis. 42, 43 To assess how all LNPs delivered DNA at once, we amplified barcodes and deep sequenced them as we previously described. 3, 4 The readout for these DNA sequencing experiments is normalized delivery, 3 which is analogous to counts per million in RNA-seq experiments (Supplementary Figure 1F) .
We first analyzed whether cholesterol structure affected LNP size. We measured the hydrodynamic diameter of all 111 LNPs individually. Oxidized, esterified, and unmodified cholesterol formulated LNPs that met our inclusion criteria 72−100%, 56−76%, and 80% of the time, respectively (Supplementary Figure 1G) . Cholesteryl oleate had the lowest percent included LNPs and the tightest diameter distribution (22−115 nm) for cholesterol-containing LNPs (Supplementary Figure 1H) . The average LNP diameter did not change with cholesterol type (Supplementary Figure 1H) . As an additional control for LNP size, we plotted normalized delivery against LNP diameter for all ∼2000 in vivo data points. The number of in vivo data points was calculated as shown in Supplementary Table 1. As we reported previously, 3, 4 we found no relationship between LNP size and delivery (Supplementary Figure 1I) . We then looked at whether this relationship improved if we split the LNPs by cholesterol variant and then plotted normalized delivery against LNP diameter (Supplementary Figure 1J−P). We did not observe an improvement in the R 2 value, suggesting that there was no trend between LNP size distribution and normalized delivery when breaking up the LNPs by cholesterol variant (Supplementary Figure 1Q) . The diameter of the pooled LNPs was similar to the diameters of the individual LNPs ( Figure 1F ). We also analyzed the delivery of naked barcode; as expected, this negative control was delivered much less efficiently than barcodes delivered by LNPs in all 18 samples ( Figure 1G,H) .
To assess how cholesterol structure affected delivery in vivo for all LNPs, we used unbiased Euclidian analysis to generate a nanoparticle-targeting heatmap (Figure 2A ). Euclidean analysis is a common bioinformatics approach 44 that "clusters" large data sets into experimental groups that behave similarly; it can be used to study barcoded LNPs. 3 The naked barcode designated by an asteriskwas easily identified; it delivered barcodes inefficiently in all samples. Euclidean analysis created three clusters; when compared to the "center" cluster, the leftand rightmost clusters had more purple, which designated higher normalized delivery (Figure 2A ). On the basis of this data visualization, we analyzed the cholesterol types in the leftand rightmost (i.e., "good") clusters and the center (i.e., "bad") cluster. LNPs formulated with esterified cholesterols were 1.4-fold enriched in the good clusters, relative to LNPs made with oxidized cholesterol. In other words, LNPs formulated with esterified cholesterols were 1.4-fold more likely to be in the left-or rightmost clusters than oxidized cholesterols. LNPs made with oxidized cholesterols were enriched by 1.3-fold in the center cluster ( Figure 2B ). Enrichment is described in Supplementary Figure 2A . On the basis of these analyses, we quantified normalized barcode delivery mediated by nanoparticles that contained esterified, unmodified, or oxidized cholesterols in all cell types in WT mice. Normalized barcode delivery mediated by LNPs made with esterified cholesterol was significantly higher than barcode delivery mediated by LNPs with regular cholesterol or oxidized cholesterol ( Figure  2C ,D, Supplementary Table 2 ). These analyses averaged delivery of each nanoparticle, including those that delivered barcodes inefficiently, across all cell types. However, many studies focus on top performing LNPs. We identified LNPs in the top 15% in each cell type and performed an enrichment analysis as described in Supplementary Figure 2A . LNP formulations that were enriched in each cell type in WT, VLDLR −/− , and LDLR −/− mice are listed in Supplementary  Figure 2B −D. We then analyzed whether particle size and biodistribution in top performing LNPs were correlated and found no significant relationship between the two (Supplementary Figure 2E −K). We performed this analysis for the whole animal (i.e., all cell types, averaged); esterified cholesterol was consistently enriched in the top 15%. LNPs formulated with esterified cholesterols were 2-fold more likely to be in the top 15% of LNPs than LNPs made with oxidized cholesterols in WT mice ( Figure 2E,F) . Taken together, these data support the hypothesis that cholesterol structure affects LNP delivery in vivo.
We performed the same analyses described above ( cholesterols performed poorly relative to esterified and unmodified cholesterol in both knockout models when quantified using average normalized delivery and enrichment. Esterified cholesterol and unmodified cholesterol performed similarly when quantified using average normalized delivery. Enrichment in the top 15% varied; esterified cholesterol outperformed unmodified cholesterol in LDLR −/− mice, but not in VLDLR −/− mice. These results support previously published data demonstrating the cholesterol trafficking receptors can affect LNP delivery. 32 On the basis of these initial analyses, we quantified the extent to which LNP delivery in LDLR −/− and VLDLR −/− mice differed from LNP delivery in WT mice. We plotted normalized delivery for all LNPs in all six cell types in WT, LDLR −/− , and VLDLR −/− mice ( Figure  3A) . If either gene affected delivery of the LNP library tested, then the R 2 value between the WT and knockout mice would decrease ( Figure 3A) . The high-throughput nature of barcoding enabled us to compare WT and knockout mice rigorously; each plot contains >650 in vivo data points ( Figure  3B ,C). We found that both LDLR and VLDLR affected delivery; the R 2 value between WT and either LDLR −/− or VLDLR −/− mice was 0.37 and 0.50, respectively. We then evaluated whether there was a cell-type-specific effect to these genes by analyzing the We did not observe clear patterns; the cell-type-specific effects of these genes on LNP delivery will need to be explored using different approaches in the future.
DNA barcode readouts quantify nanoparticle biodistribution, which is required, but not sufficient for functional RNA delivery into the cytoplasm. Cytoplasmic RNA delivery is necessary for successful RNA interference as well as gene editing. RNA-mediated in vivo genome editing is important for studying biological pathways and understanding the potential differential effects that genes have on different cell types. To analyze whether LNPs formulated with esterified cholesterols functionally delivered RNAs in vivo, we selected an LNP for further analysis. To directly compare esterified cholesterol and unmodified cholesterolwhich is the current gold standard in the fieldwe chose an LNP molar ratio ( Figure 4A ) that made up three of the top five LNPs in hepatic endothelial cells in our barcoding screen ( Figure 4B ). Hepatic endothelial cells have with few exceptions 45 been difficult to target systemically and, as a result, have not been edited by Cas9 after systemic administration of single guide RNAs (sgRNAs). We formulated two LNPs with a 50:29:11:10 molar ratio of 7C1, cholesterol, C 14 PEG 2000 , and 18:1 Lyso PC, respectively. LNPoleate contained cholesteryl oleate, whereas LNP-unmod contained unmodified cholesterol. This molar ratio resulted in small, stable LNPs when formulated to carry siRNA and sgRNA (Supplementary Figure 4A) . We considered formulating LNPs with cholesteryl stearate; however, LNPs formulated with stearate were stable less frequently (Supplementary Figure  1H) .
We formulated LNP-oleate and LNP-unmod to carry a chemically modified 46 sgRNA targeting GFP (Supplementary Figure 4B ) and injected these nanoparticles intravenously into mice that express SpCas9-P2A-GFP under a CAG promoter. Five days after a 1.0 mg/kg sgRNA injection, we isolated hepatic endothelial cells and hepatocytes using FACS and quantified insertions and deletions ("indels") using tracking indels with decomposition (TIDE). 47 Delivery to hepatic endothelial cells was highly efficient, leading to 41% editing at the target GFP locus ( Figure 4C ). LNP-unmod was efficient (31% indels), but less so than LNP-oleate. Oleate delivery was particularly specific; the indel ratio of hepatic endothelial cells:hepatocytes was 3 ( Figure 4D,E) . In contrast, all previous systemically administered nanoparticle gene editing has occurred preferentially in hepatocytes. 46,48−50 This is the first report of sgRNA-mediated in vivo editing in hepatic endothelial cells.
We assessed the activity of LNP-oleate and LNP-unmod using siRNA. siRNA-based therapeutics have successfully treated disease in hepatocytes; understanding how to target hepatic endothelial cells has the potential to lead to therapeutics that target endothelial cell driven disease. We intravenously injected WT mice with 1.5 mg/kg siRNA targeting the endothelial specific gene ICAM-2 (Supplementary Figure 4C ). Both siICAM-2 and the control siRNA targeting luciferase (siLuc) were chemically modified to reduce immune stimulation and promote on-target activity. 6, 34, 35 Three days after siICAM-2 treatment with LNP-oleate or LNP-unmod, ICAM-2 protein expression, measured by mean fluorescent intensity (MFI), decreased by 74% and 75%, respectively, in hepatic endothelial cells compared to PBS-and siLuc-treated mice ( Figure 4F ). Following treatment, mice injected with sgRNA or siRNA gained weight as quickly as PBS-treated mice (Supplementary Figure 4D,E) .
CONCLUSION
Despite being a universal problem that limits all genetic therapies, 51−54 it is still difficult to predict which nanoparticles will deliver RNAs in vivo. Here we demonstrated that in vivo screening can be used to identify LNP traits that affect delivery. Our study was powered by strong statistical analyses; we compared nearly 2000 in vivo drug delivery data points. These data support the hypothesis that modified cholesterols can affect nanoparticle targeting.
We identified an LNP formulation that efficiently targeted hepatic endothelial cells in vivo. The LNP preferentially delivered sgRNAs to hepatic endothelial cells 3 times more efficiently than hepatocytes. This is uncommon; almost all reported LNPs preferentially target hepatocytes. 7−12,46,48−50 Targeting hepatic endothelial cells is important given the active role they play in establishing the liver microenvironment and driving fibrosis, inflammation, primary tumor growth, and metastasis. 55 Although we do not know the mechanism for preferential targeting to hepatic endothelial cells over hepatocytes, literature suggests that LNPs interact with serum proteins, which may promote delivery to specific cell types. We anticipate future studies utilizing LNP-oleate to treat hepatic endothelial cell disease and study fundamental biological questions related to hepatic endothelial cell signaling. More generally, our data demonstrate that cholesterol can be viewed as another modular LNP component that can be rationally designed to improve in vivo delivery, demonstrating that DNA barcoding is a powerful tool that can identify material properties that influence nanoparticle delivery in vivo.
This study complements previous in vitro work relating siRNA delivery to the structure of the cationic or ionizable lipid-like compound. 6−10 This work also supports the idea that LNPs can be rationally designed with cholesterol structures that closely mimic natural LDL, HDL, or VDLR to improve delivery 56 or rationally designed to interact with natural cholesterol trafficking pathways. Given that cholesterol trafficking is perturbed in many diseases, and can be altered when commonly prescribed drugs are taken, 17 this also suggests that the efficacy of an LNP may vary with the patient population. One important limitation to this work is that the mechanism by which delivery of LNPs with esterified cholesterol is improved remains unclear. We hypothesize that this effect is mediated by differential interactions with serum proteins and the protein corona. 57 Future studies detailing changes in target cell signaling and protein coronas will be required to confirm or disprove this proposed mechanism.
METHODS/EXPERIMENTAL
Nanoparticle Formulation. Nanoparticles were formulated in a microfluidic device by mixing DNA with 7C1, PEG, cholesterol, and a helper lipid, as previously described. 4,6,34−36,58−62 Nanoparticles were made with variable mole ratios of these constituents. The nucleic acid (e.g., DNA barcode, siRNA, sgRNA) was diluted in 10 mM citrate buffer (Teknova) and loaded into a syringe (Hamilton Company). The materials making up the nanoparticle (7C1, cholesterol, PEG, and helper lipid) were diluted in 100% ethanol and loaded into a second syringe. The citrate phase and ethanol phase were mixed together in a microfluidic device at 600 and 200 μL/min, respectively. Helper lipids were purchased from Avanti Polar Lipids.
DNA Barcoding. Each chemically distinct LNP was formulated to carry its own distinct DNA barcode ( Figure 1A,B) . For example, LNP1 carried DNA barcode 1, while the chemically distinct LNP2 carried DNA barcode 2. The DNA barcodes (IDT) were designed rationally with universal primer sites and an eight-nucleotide barcode sequence, similar to what we previously described. 3, 4 Three nucleotides on the 5′ and 3′ ends were modified with phosphorothioates to reduce exonuclease degradation and improve DNA barcode stability. To ensure equal amplification of each sequence, we included universal forward and reverse primer regions on all barcodes. Each barcode was distinguished using a distinct 8nt sequence. An 8nt sequence can generate over 4 8 (65 536) distinct barcodes. We used 156 distinct 8nt sequences designed to prevent sequence bleaching on the Illumina MiniSeq sequencing machine.
Nanoparticle Characterization. LNP hydrodynamic diameter was measured using DLS (DynaPro plate reader II, Wyatt). LNPs were diluted in sterile 1× phosphate-buffered saline (PBS, Invitrogen) to a concentration of ∼0.06 μg/mL and analyzed. LNPs were included if they met three criteria: diameter >20 nm, diameter <200 nm, and autocorrelation function with only 1 inflection point. Particles that met these criteria were pooled and dialyzed in 1× PBS and sterile filtered with a 0.22 μm filter.
Animal Experiments. All animal experiments were performed in accordance with the Georgia Institute of Technology's Institutional Animal Care and Use Committee (IACUC). Female C57BL/6J (#000664), LDLR −/− (#002207), VLDLR −/− (#002529), and SpCas9 constitutive mice (#026179) were purchased from Jackson Laboratory. In all experiments, mice were 5−8 weeks old, and N = 3 or 4 mice per group were injected intravenously via the lateral tail vein (Supplementary Table 3 ). The nanoparticle concentration was determined using a NanoDrop (Thermo Scientific).
Cell Isolation and Staining. Mice were perfused with 20 mL of 1× PBS through the right atrium. The lungs, spleen, and liver were isolated immediately following perfusion. Tissues were finely cut and then placed in a digestive enzyme solution with collagenase type I (Sigma-Aldrich), collagenase XI (Sigma-Aldrich), and hyaluronidase (Sigma-Aldrich) at 37°C and 550 rpm for 45 min. The digestive enzyme for heart and spleen included collagenase IV (SigmaAldrich).
6,34,35 Digested tissues were passed through a 70 μm filter, and red blood cells were lysed. Cells were stained to identify specific ACS Nano Endothelial RNAi. C57BL/6J mice were injected with 1.5 mg/kg siLUC or 1.5 mg/kg siICAM2 (AxoLabs). siRNAs were chemically modified at the 2′ position to increase stability and specificity and negate immunostimulation. Both siGFP and siICAM2 sequences have been previously reported several times. 6, 34, 35 Seventy-two hours after injection, tissues were isolated and protein expression was quantified as MFI using flow cytometry. ICAM2MFI in PBS-treated mice was normalized to 100%, and all treated groups were compared to this control group.
Endothelial Gene Editing. Constitutive SpCas9 mice were injected with LNP-unmod or LNP-oleate delivering e-sgGFP (AxoLabs) at a dose of 1.0 mg/kg. Five days after injection, tissues were isolated, and cell types were sorted using FACs. DNA was extracted using QuickExtract, and Sanger sequencing was conducted by Eton Biosciences. Indel formation was measured by TIDE (https://tide-calculator.nki.nl).
PCR Amplification. All samples were amplified and prepared for sequencing using a two-step, nested PCR protocol. More specifically, 1 μL of each primer (10 μM reverse/forward) was added to 5 μL of Kapa HiFi 2× master mix, 2 μL of sterile H 2 O, and 1 μL of DNA template. This first PCR reaction was run for 30 cycles. The second PCR, to add Nextera XT chemistry, indices, and i5/i7 adapter regions was run for 5−10 cycles and used the product from "PCR 1" as template. If this initial PCR reaction did not produce clear bands, the primer concentrations, DNA template input, PCR temperature, and number of cycles were optimized for individual samples. The PCR amplicon was isolated using BluePippin (Sage Science).
Deep Sequencing. Illumina deep sequencing was conducted in Georgia Tech's Molecular Evolution core. Runs were performed on an Illumina Miniseq. Primers were designed based on Nextera XT adapter sequences.
Data Normalization. Counts for each particle, per tissue, were normalized to the barcoded LNP mixture injected into mice, as previously described. 4 This "input" DNA was used to normalize DNA counts from the cells and tissues.
Data Analysis. Sequencing results were processed using a custom Python-based tool to extract raw barcode counts for each tissue. These raw counts were then normalized with an R script prior to further analysis. Statistical analyses were done using GraphPad Prism 7. Correlation analyses were run assuming a Gaussian distribution in order to obtain Pearson correlation coefficients. R 2 values (0−1) were computed by squaring Pearson correlation coefficients. Data are plotted as mean ± standard error of the mean unless otherwise stated.
Data Access. The data, analyses, and scripts used to generate all figures in the paper are available upon request to J.E.D. or dahlmanlab.org.
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